Metabolic syndrome (MetS) is a complex condition characterized by obesity, dyslipidemia, and hypertension, and is closely linked to inflammation. It serves as a significant predictor for the development of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD). Incretin-based therapies, particularly those involving glucagon-like peptide-1 receptor (GLP-1R) agonists, have been well-established in the treatment of T2DM and offer cardio-renal protection. Recent advancements have expanded their role to include weight management in obese individuals, with notable approvals such as liraglutide and semaglutide by the FDA for obesity treatment. Emerging evidence suggests that these therapies also reduce the severity of MetS, abdominal obesity, and inflammation, with potential benefits for NAFLD and NASH. Despite these promising findings, the full scope of their benefits in preventing T2DM and treating MetS and related disorders remains unclear, necessitating further investigation into their mechanisms and broader therapeutic potential.
This research topic aims to collect and publish recent evidence and current knowledge to elucidate the underlying mechanisms of incretin-based agonists in treating metabolic syndrome beyond their role in obesity management. The focus will be on understanding the effects of specific agonists such as liraglutide, exenatide, dulaglutide, semaglutide, and retatrutide. Additionally, the research will explore the potential of these therapies in treating prediabetic patients and their broader implications for metabolic health.
To gather further insights into the multifaceted role of incretin-based therapies, we welcome articles addressing, but not limited to, the following themes:
- Clinical trials and experimental studies investigating the long-term effects of incretin-based agonists on metabolic syndrome.
- Safety and efficacy assessments of incretin-based agonists in metabolic syndrome management.
- Exploring the role of incretin-based agonists in preventing and treating NAFLD/NASH and cardio-renal diseases.
- Molecular insights into the action of incretin-based agonists and their potential in attenuating inflammatory responses.
We invite contributions in the form of review papers, basic science research, clinical trials, and short communications, aimed at enriching our understanding of incretin-based agonists in metabolic syndrome.
Metabolic syndrome (MetS) is a complex condition characterized by obesity, dyslipidemia, and hypertension, and is closely linked to inflammation. It serves as a significant predictor for the development of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD). Incretin-based therapies, particularly those involving glucagon-like peptide-1 receptor (GLP-1R) agonists, have been well-established in the treatment of T2DM and offer cardio-renal protection. Recent advancements have expanded their role to include weight management in obese individuals, with notable approvals such as liraglutide and semaglutide by the FDA for obesity treatment. Emerging evidence suggests that these therapies also reduce the severity of MetS, abdominal obesity, and inflammation, with potential benefits for NAFLD and NASH. Despite these promising findings, the full scope of their benefits in preventing T2DM and treating MetS and related disorders remains unclear, necessitating further investigation into their mechanisms and broader therapeutic potential.
This research topic aims to collect and publish recent evidence and current knowledge to elucidate the underlying mechanisms of incretin-based agonists in treating metabolic syndrome beyond their role in obesity management. The focus will be on understanding the effects of specific agonists such as liraglutide, exenatide, dulaglutide, semaglutide, and retatrutide. Additionally, the research will explore the potential of these therapies in treating prediabetic patients and their broader implications for metabolic health.
To gather further insights into the multifaceted role of incretin-based therapies, we welcome articles addressing, but not limited to, the following themes:
- Clinical trials and experimental studies investigating the long-term effects of incretin-based agonists on metabolic syndrome.
- Safety and efficacy assessments of incretin-based agonists in metabolic syndrome management.
- Exploring the role of incretin-based agonists in preventing and treating NAFLD/NASH and cardio-renal diseases.
- Molecular insights into the action of incretin-based agonists and their potential in attenuating inflammatory responses.
We invite contributions in the form of review papers, basic science research, clinical trials, and short communications, aimed at enriching our understanding of incretin-based agonists in metabolic syndrome.